Close Menu
Home › Qiagen Syndromic Testing System, Respiratory Panel Garner FDA Clearance

Qiagen Syndromic Testing System, Respiratory Panel Garner FDA Clearance

May 20, 2019

NEW YORK (GenomeWeb) – Qiagen said today that its QiaStat-Dx syndromic testing system and multiplex respiratory pathogen panel have received 510(k) clearance from the US Food and Drug Administration.

With the clearance, Qiagen is commercially launching the products in the US, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jul
30
Featured Webinar

Single-Cell Sequencing Reveals Clonal Heterogeneity in Acute Lymphoblastic Leukemia

Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

What's Popular?

In PCR

  1. BD Files Patent Infringement Suit Against NeuMoDx

  2. BD High-Throughput MDx System CE Marked

  3. Mayo Clinic Spinout Developing Multiomics Blood Test to Identify Obesity Phenotypes

    Premium

  4. Japanese Regulators Approve Invivoscribe Assay as CDx for Daiichi Sankyo AML Drug

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.